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Abstract
Research into acupuncture has had ripple effects beyond the field of acupuncture. This paper identifies five
exemplars to illustrate that there is tangible evidence of the way insights gleaned from acupuncture research have
informed biomedical research, practice, or policy. The first exemplar documents how early research into acu-
puncture analgesia has expanded into neuroimaging research, broadening physiologic understanding and treatment
of chronic pain. The second describes how the acupuncture needle has become a tool to enhance biomedical
knowledge of connective tissue. The third exemplar, which illustrates use of a modified acupuncture needle as a
sham device, focuses on emergent understanding of placebo effects and, in turn, on insights into therapeutic
encounters in treatments unrelated to acupuncture. The fourth exemplar documents that two medical devices now
in widespread use were inspired by acupuncture: transcutaneous electrical nerve stimulators for pain control and
antinausea wrist bands. The final exemplar describes how pragmatic clinical trial designs applied in acupuncture
research have informed current general interest in comparative effectiveness research. In conclusion, these ex-
emplars of unanticipated outcomes of acupuncture research comprise an additional rationale for continued support
of basic and clinical research evaluating acupuncture and other under-researched therapies.
Background
W
ithin the history of medicine, there are examples
of scientific discoveries that emerged from unrelated
or marginally related research. Such events often result from
cross-fertilization of ideas, as for example when the emergent
concept of autoimmunity catalyzed the shift in understanding
of type 1 diabetes from a genetically determined endocrine
imbalance to an organ-specific autoimmune disorder.1 New
ideas also arise when research efforts to target specific
questions reveal unexpected findings, for example, the ef-
fectiveness of sildenafil for treating erectile dysfunction
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(observed during its testing for coronary artery disease) and
iproniazid, an early treatment for depression (during testing
as a chemotherapeutic agent for tuberculosis).2 The present
paper examines results from acupuncture research that have
affected biomedicine.
A major impetus to acupuncture research in the United
States occurred in 1998, when the National Center for
Complementary and Alternative Medicine (now the Na-
tional Center for Complementary and Integrative Health)
was established within the National Institutes of Health
(NIH). This support has led to important research findings
regarding acupuncture’s effectiveness,3 as well as advances
in the understanding of acupuncture’s mechanisms of ac-
tion.4 Despite this considerable progress, debate remains
regarding the interpretation and acceptance of the evidence
base for acupuncture and the value of future research.5,6
Missing from these reviews and discussions is a consider-
ation of the often unexpected and broad-reaching discov-
eries that emerge when the traditions of biomedicine and
acupuncture meet in the context of objective and systematic
scientific exploration.
This paper documents how ripple effects of acupuncture
research have traveled beyond the field of acupuncture to
affect several aspects of biomedicine. Specifically, acupunc-
ture research has (1) expanded scientific and clinical knowl-
edge in the fields of chronic pain, connective tissue, and
placebo effects; (2) spawned the design of novel medical
devices, which have increased treatment options in the areas
of pain control and nausea suppression; and (3) furthered the
development of research methods through the design and
implementation of pragmatic clinical trials for chronic pain.
Few are aware of the origins and pathways of these devel-
opments because they are now sufficiently integrated within
the knowledge base and practice of biomedicine. The paper
concludes by proposing that these exemplars provide evi-
dence that acupuncture research has broadened biomedical
understanding with regard to research, practice, and policy, as
well as strengthening the case for continued support of basic
and clinical research evaluating acupuncture and other un-
derresearched therapies.
Exemplars
Acupuncture, endorphins, and analgesia research
Among the earliest research findings pertinent to both
acupuncture and biomedicine are the demonstrations in
animal models and humans that acupuncture analgesia is
mediated in part by endogenous opioids.7,8 These findings,
including similar pharmacologic sensitivities of morphine
analgesia and acupuncture analgesia and results indicating
that different types of ‘‘endorphins’’ are released by dif-
ferent frequencies of electro-acupuncture, generated sub-
stantial interest within the biomedical community. Timely
reviews appeared in high-profile journals,9,10 and the acu-
puncture/endogenous opioid connection was endorsed at the
1997 NIH Consensus Conference on Acupuncture.11
More recently, biomedical research on pain has seen sig-
nificant contributions from acupuncture neuroimaging re-
search.4,12 For example, positron emission tomography
detected an increase of mu-opioid receptor–binding potential
in multiple brain regions that correlated with acupuncture-
associated reduction in fibromyalgia pain.13 This specific
demonstration of altered brain activity in patients with fi-
bromyalgia has been cited as an important precedent in
studies on the pathophysiology of other chronic pain condi-
tions.14,15
In a functional magnetic resonance imaging study, pa-
tients with carpal tunnel syndrome whose subjective and
objective symptoms improved following acupuncture dem-
onstrated a return to normal mapping of their carpal tunnel
syndrome–affected digits on the primary somatosensory
cortex (S1).16 This finding of central nervous system–related
peripheral pathology has been referenced in publications on
neuroplasticity in carpal tunnel syndrome17,18 and neuro-
pathic pain.19
Acupuncture neuroimaging research has also identified a
novel brain-based marker for clinical pain perception. Pa-
tients with fibromyalgia show elevation of an intrinsic brain
connectivity marker that correlates significantly with pain
intensity20 and is normalized following successful acu-
puncture analgesia therapy.21 This research has been cited in
several recent reviews for its importance as an objective
biological marker for pain neuroimaging research.22–24
The translational acupuncture research examples sum-
marized above have contributed to the development of
broader clinical guidelines and reimbursement policies re-
lated to pain, and to the use of acupuncture as an inter-
vention within mainstream medicine. With an increased
public profile and insurance reimbursement, pain is now the
leading indication for acupuncture use, as revealed in sur-
veys from the United States25 and Europe.26 Use has in-
creased in parallel with greater acceptance of acupuncture
by physicians and allied specialists. For example, in the
United Kingdom about one third of the 4 million annual
acupuncture sessions are provided (free at point of delivery)
within the National Health Service by biomedical practi-
tioners (doctors and physiotherapists).27 In Germany,
around 30,000 physicians, some of whom contributed to
high-profile randomized controlled trials of acupuncture for
chronic pain,28 currently provide acupuncture, which is re-
imbursed by public health insurance.29
Connective tissue in health and disease
Connective tissue has long been the orphan child of
medicine. Although it is part of the musculoskeletal system,
connective tissue is basically absent from orthopedic and
rheumatology textbooks, which are principally concerned
with bones, muscles, and cartilage. In current textbooks, the
nonspecialized connective tissues forming the fascia that
envelop all muscles, nerves bones, and blood vessels are
typically allotted a short paragraph, if mentioned at all.
Although the consequence of connective tissue injury—
scarring and adhesion formation—is well recognized, the
secondary effects of these adhesions, in particular their
relevance to chronic pain, is little discussed.30
However, interest in connective tissue has been growing,
and acupuncture research has contributed to this trend within
biomedicine. One area that has attracted researchers to this
field has been the study of mechanotransduction, or the
mechanisms by which cells perceive, interpret, and respond
to mechanical forces present in tissues.31 Through specialized
protein complexes, cells sense outside forces and ‘‘trans-
duce’’ these mechanical signals into cellular responses, such
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as activation/deactivation of signaling molecules, transloca-
tion of transcription factors into the nucleus, and changes in
gene expression. But current research on mechanotransduc-
tion has a well-recognized limitation: Almost all of its
knowledge is derived from cultured cells. Extension of this
work into whole, live tissue has resulted from studies in
which the acupuncture needle provides a method to deliver a
precise mechanical signal that can produce dose-dependent
responses in areolar connective tissue fibroblasts.32,33 Sus-
tained stretching of tissue is inherent to this response and has
been shown to cause local purinergic signaling and active,
cell-mediated tissue relaxation.34 Before experiments with the
acupuncture needle, these functions of fibroblasts were un-
known. Thus, novel insights gleaned from acupuncture-
related research have led to an improved understanding of
basic mechanobiology.31,35–37
Acupuncture-related studies on connective tissue also
have contributed to a resurgence of interest and greater
understanding of connective tissue pathology associated
with chronic musculoskeletal pain and fibrotic diseases.38,39
The areolar connective tissue layers that wind around the
needle and respond to acupuncture needle manipulation are
the same layers that normally allow gliding between adja-
cent layers of fascia during normal movement and become
abnormal in musculoskeletal pain.40 Recent ultrasound
studies have shown that the connective tissues surrounding
the muscles of the back are thicker in people with chronic
low back pain than in control participants without back
pain41; similar results have been reported in patients with
chronic pelvic pain.42
These insights and new avenues of investigation into
mechanobiology and connective tissue pathophysiology are
not likely to have occurred without the initial research that
used acupuncture needles to interact specifically with loose
connective tissue.
Toward a better understanding of placebo effects
Placebo effects, or nonspecific treatment effects, occur in
preclinical research, clinical practice, and randomized con-
trolled clinical trials, with large effect sizes in functional
disorders such as chronic pain43 and depression.44 This
section highlights how acupuncture research on chronic pain
has contributed to the understanding and potential clinical
use of placebo effects in biomedicine.
The use of the sham acupuncture needle as a unique pla-
cebo device has assisted researchers in identifying key
components of treatment that may enhance the effect of
placebo. In a seminal study by Kaptchuk et al., patients with
irritable bowel syndrome reported increasing symptom relief
with escalating ‘‘doses’’ of placebo: observation alone, ob-
servation plus sham acupuncture, and observation plus sham
acupuncture plus positive patient-provider relationship.45
This study has significantly affected the field of gastroenter-
ology, enhancing appreciation of the doctor as a ‘‘walking
placebo,’’46 and highlighting the potential that arises from
placebo research for patients with chronic abdominal symp-
toms.47 This specific line of research in irritable bowel syn-
drome also set the stage for exploring genomic effects on
placebo response,48 addressing ethical questions related to
placebo effects,49 the first open-label placebo pill study,50 and
other novel placebo study research designs.51
Acupuncture research has also been credited with iden-
tifying serum and genetic biomarkers associated with the
placebo response.52 These markers include serum osteo-
protegerin and tumor necrosis factor–related weak inducer
of apoptosis53 as well as catecholamine O-methyl transfer-
ase functional val158met polymorphism.48
In summary, acupuncture research has contributed to the
renewed interest in the role of placebo in clinical care and
has helped advance placebo research in three major areas:
(1) the rate and the degree of response to placebo, which can
be high, leading to prolonged symptom (often pain) relief in
up to half of the participants52,54; (2) the important role of
the provider-patient relationship in the therapeutic response
to placebo45,55; and (3) identification of additional bio-
markers associated with placebo response.53,56 These inno-
vative findings provide a scientific basis for ethically
enhancing the placebo effect in the clinical setting by
strengthening the provider-patient relationship (e.g., com-
munications and clear explanation of possible benefits of a
treatment46,54) and by optimizing the therapeutic environ-
ment and rituals.49
Acupuncture-related devices that have affected
biomedicine
The development of several currently used biomedical
devices has clear links to acupuncture-related research. This
section highlights two widely used devices: transcutaneous
electrical nerve stimulation (TENS) units for analgesia and
acupressure bands for relief of nausea.
Acupuncture and TENS. The modern TENS unit as a
means of pain relief was developed from a technique of
dorsal column electroanalgesia by C. Norman Shealy, MD,
in the early 1970s.57,58 According to Shealy, ‘‘I began
stimulating acupuncture needles with electrical energy in the
mid 60’s. Later, without needles, I introduced TENS.’’59
This led to a TENS patent issued to Medtronic in 1974.60
In the United States, TENS is a reimbursable medical
procedure for pain relief in both private and public insurance
sectors. In the private sector, TENS is coded based on the
American Medical Association (AMA) Current Procedural
Terminology (CPT 97014 or 64550) and in the public sector
based on the AMA’s Healthcare Common Procedure Coding
System (HCPCS- G0283).61 The effect of TENS on the
medical field at large is also reflected in U.S.-based insur-
ance guidelines; for example, Blue Cross–Blue Shield As-
sociation currently supports the use of this device for
chronic spinal pain (neck or back).62 TENS devices have
received U.S. Food and Drug Administration (FDA) ap-
proval for both pain relief and the prevention of pain.63
Acupuncture and acupressure bands. Numerous acu-
pressure devices (e.g., Sea-Band, Sea-Band Ltd., Leices-
tershire, United Kingdom) are available on the open market,
most often sold as a means to relieve nausea and vomiting.
The history of these devices is inseparably linked to the
clinical practice of acupuncture and acupressure, with clin-
ical research reinforcing their acceptance. The earliest re-
search trials were initiated in Ireland by J.W. Dundee, who
had observed physicians in China teaching patients to press
on acupuncture point PC6, located on the inner wrist.64
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Dundee and colleagues were among the first to conduct
randomized controlled trials to demonstrate the antiemetic
effectiveness of acupuncture,65 a finding replicated with
manual acupressure using a wristband device.66 Numerous
subsequent acupuncture and acupressure trials have been
evaluated in systematic reviews of nausea and emesis as-
sociated with postoperative recovery67 and chemotherapy.68
The 1997 NIH Consensus Conference on Acupuncture
reported promising results from stimulation of PC6 for
postoperative and chemotherapy-related nausea and vomit-
ing.11 Several PC6 acupressure stimulation devices have
received FDA approval for nausea control and are now
available on the open market.69
The common use of these acupressure devices, combined
with clinical research results, has translated into several
international clinical guidelines within biomedicine re-
commending acupressure. Such guidelines include those of
the Society of Obstetrics & Gynecology of Canada on the
management of nausea and vomiting in pregnancy,70 the
U.S. Agency for Healthcare Research and Quality,71 and the
United Kingdom’s National Institute for Health and Care
Excellence (NICE).72,73
Pragmatic clinical trials
The evolution of clinical research in biomedicine toward
more pragmatic randomized controlled trials, a method often
encouraged in comparative effectiveness research,74 was
informed by earlier research involving pragmatic trials of
acupuncture for chronic pain conditions in the United
Kingdom with recruitment starting in 199975,76 and in Ger-
many starting in 2001.28 The need for a more pragmatic ap-
proach was supported in 2003 by Tunis and colleagues,77
who argued that there was a paucity of published research
designed to directly answer questions faced by policymakers,
clinicians, and patients. Most trials, they observed, used ef-
ficacy or explanatory designs that evaluated the degree to
which a specific component of an intervention can outper-
form a placebo or sham procedure. Their recommendations to
increase the value of clinical research for decision-making in
health policy and practice included placing a higher priority
on pragmatic (practical) clinical trials.
The York Acupuncture for Back Pain trial provides an
example of how a pragmatic acupuncture trial has been
influential beyond the field of acupuncture research. The
trial, in which 241 patients received a short course of up to
10 acupuncture sessions plus usual care or usual care alone,
provided evidence that acupuncture is both clinically ef-
fective and cost-effective at 24 months after randomiza-
tion.75 This study was cited as the exemplar of a ‘‘highly
pragmatic’’ trial in the Consolidated Standards of Reporting
Trials statement extension for pragmatic trials, published in
2008.78
Since 2009, comparative effectiveness research, which
compares at least two interventions, each with the potential to
be ‘‘best practice,’’ has been promoted by the U.S.-based
Institute ofMedicine, much along the same lines as theUnited
Kingdom and German trials, with a focus on assisting con-
sumers, clinicians, purchasers, and policymakers to make
informed decisions that will improve healthcare at both the
individual and population levels.74 To this end, pragmatic
trials are featured by the Institute of Medicine as one of the
most important research methods within comparative effec-
tiveness research. The recently created Patient-Centered
Outcomes Research Institute, which directly supports large
pragmatic trials to evaluate patient-centered outcomes,79
reflects the expanding interest in pragmatic trials.
The United Kingdom pragmatic trials of acupuncture for
back pain75 and for chronic headache and migraine76 both
demonstrated clear evidence of cost-effectiveness as well as
clinical effectiveness.80,81 As a result, these trials contrib-
uted to a major shift in health policy within biomedicine.
Both were cited by NICE as providing key evidence for the
NICE recommendations that acupuncture should be offered
within the National Health Service as an option for both
persistent low back pain82 and headache/migraine.83 The
findings of the German acupuncture trials28 contributed to a
2006 decision by that country’s health authorities in favor of
insurance-based reimbursement to physicians providing
acupuncture for osteoarthritis of the knee and chronic low
back pain.29
Discussion
To the authors’ knowledge, this is the first attempt to
consider the effect of acupuncture research beyond the field
of acupuncture itself, in particular its effect on research,
practice, and healthcare policy within contemporary bio-
medicine. This article sought not only to identify the clearest
examples of this scientific cross-fertilization but also to
present a variety of topic areas not limited to different
conditions for which acupuncture efficacy or effectiveness
has been assessed. Thus, while this article described the
effect of acupuncture research on biomedical understanding
of chronic pain conditions and on the emerging role of
connective tissue, it also documented clear instances of ef-
fects in the disparate areas of medical devices, placebo ef-
fects, and research methods.
Central to this paper is the question of how to define and
recognize ‘‘effect.’’ An initial realization was that the varied
nature of the included topics would preclude an across-the-
board application of a single criterion. Nevertheless, the
consensus position was to seek tangible indications that
information gleaned from acupuncture research had broad-
ened the biomedical framework in regard to research,
practice, or policy. Following this guideline, this article
described, for example, how research on connective tissue
has been advanced by use of the acupuncture needle as a
probe in intact tissue. In the realm of practice and policy, we
described two acupuncture-related devices that have re-
ceived FDA approval as effective treatment options within
mainstream medicine.
Similar findings of significant insights have been reported
in other areas of research, especially in the scientific eval-
uation of poorly understood phenomena. Promise of novel
‘‘spin-offs’’ was a key argument underlying funding and
investment in the NIH Office of Rare Diseases.84 As an
example, the Wyss Institute for Biologically Inspired En-
gineering, on the Harvard Medical School campus, has
consciously fostered cross-disciplinary research by assem-
bling a diverse faculty that ‘‘uses Nature’s design principles
to develop bio-inspired materials and devices that will
transform medicine and create a more sustainable world.’’85
Similarly, the Media Lab on the Massachusetts Institute of
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Technology campus actively promotes an ‘‘antidisciplinary
culture, encouraging the mixing and matching of seemingly
disparate research areas’’ to create ‘‘disruptive technologies.’’86
In light of such institutional efforts to foster ‘‘silo-busting’’
research, conscious efforts to engender unanticipated in-
sights should be considered as future research invest-
ment strategies for acupuncture and other under-researched
therapies.
This review has limitations. It is a narrative one based on
exemplars rather than a systematic review or an exhaustive
presentation on all such instances of acupuncture influenc-
ing biomedicine. The authors are potentially influenced by
their own research and clinical expertise. Additionally, this
article has not explicitly explored the many ways that bio-
medicine has influenced acupuncture.
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